EUVIMEDEUVIMED entdecken
Validierungsstudie

Development and initial validation of the Cognitive Change Scale (CCS)

Anne Kever iD, Lauren B Heuer, Leila Simani iD, Victoria M Leavitt iD

Multiple Sclerosis Journal · 2024

DOI: 10.1177/13524585241290102 ↗

Kurz gefasst

Validierungsstudie in der Zeitschrift Multiple Sclerosis Journal, 2024. Verfasst von Anne Kever und 3 weiteren Autor:innen. Beteiligte Einrichtung: St. Michael's Hospital, Barlo Multiple Sclerosis Centre, Toronto, ON, Canada. Hauptthemen laut MEDLINE: Multiple Sclerosis, Cognitive Dysfunction. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 36 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Cognitive impairment is common in neurologic diseases. Precise measurement of cognitive change over time is necessary for isolating disease-related patterns from normal age-related decline. Existing measures of subjective cognition, however, focus on present status. There is, to our knowledge, no currently available self-report measure of cognitive change. We therefore developed the Cognitive Change Scale (CCS), which assesses perceived cognitive change in neurologic populations.

Methods

A systematic mixed-methods process was followed for the scale design and validation. Associations of CCS responses to demographics, mood, and fatigue were examined in 131 persons with multiple sclerosis. A total of 46 participants also completed a cognitive test battery. Correlations of test scores with CCS responses were calculated.

Results

The 17-item CCS showed good reliability and validity. Results of exploratory and confirmatory factor analyses supported a four-factor structure, with items reflecting change in (1) general cognition, (2) language and executive function, (3) external feedback, and (4) use of coping strategies. Positive relationships of CCS scores with fatigue, depression, and anxiety were observed. Correlations of CCS scores with cognitive test performance did not reach significance.

Conclusion

The CCS may be a useful cognitive outcome tool for treatment trials in neurologic populations.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Multiple SclerosisCognitive DysfunctionHumansFemaleMaleMiddle AgedAdultReproducibility of ResultsNeuropsychological TestsPsychometricsCognitionAged

Stichwörter der Autor:innen

Multiple sclerosiscognitive changescale validation

Autor:innen und Institutionen

  • St. Michael's Hospital, Barlo Multiple Sclerosis Centre, Toronto, ON, Canada.
  • Cognitive Neuroscience Division, Department of Neurology, Columbia University Irving Medical Center, New York, NY, USA.

ORCID-Profile: Anne Kever, Leila Simani, Victoria M Leavitt

Zitieren

APA

Kever, A., Heuer, L. B., Simani, L., & Leavitt, V. M. (2024). Development and initial validation of the Cognitive Change Scale (CCS). Multiple Sclerosis Journal. https://doi.org/10.1177/13524585241290102

Vancouver

Kever A, Heuer LB, Simani L, Leavitt VM. Development and initial validation of the Cognitive Change Scale (CCS). Multiple Sclerosis Journal. 2024. doi:10.1177/13524585241290102

BibTeX
@article{Kever2024,
  author = {Kever, Anne and Heuer, Lauren B and Simani, Leila and Leavitt, Victoria M},
  title = {Development and initial validation of the Cognitive Change Scale (CCS)},
  journal = {Multiple Sclerosis Journal},
  year = {2024},
  doi = {10.1177/13524585241290102}
}
Kostenlos starten →